•  
  •  
 

Abstract

Background: Oral cancer is a major cause of premature mortality in Thailand. This study examines survival and prognostic factors in a northeastern tertiary-care setting.

Methods: A hospital-based retrospective cohort study was conducted using the Cancer Registry and medical records in a tertiary care hospital in Northeastern, Thailand. Patients diagnosed with oral cancer between January 2005 and December 2015 and followed until death or February 2020. Overall survival was estimated using the Kaplan–Meier method. Cox proportional hazards models were used to assess factors associated with mortality

Results: The median survival time was 18.67 months (95% confidence interval [CI]: 15.70–22.83). It revealed that older age (51–69: adjusted Hazard Ratio [AHR] = 1.34, 95%CI: 1.06-1.69; ≥70: AHR = 1.85, 95%CI: 1.42-2.41), advanced stage (III–IV: AHR = 1.99, 95%CI: 1.47-2.69) or unknown stage (AHR = 1.53, 95%CI: 1.04-2.26), distant metastases (AHR = 1.64, 95%CI: 1.21-2.22), several primary tumor sites (e.g., tongue AHR = 1.82, 95%CI: 1.30-2.55; oropharynx AHR = 1.89, 95%CI: 1.26-2.84), and surgery (AHR = 1.88, 95%CI: 1.49-2.39) were associated with mortality. In contrast, subjects who were female sex (AHR = 0.77, 95%CI: 0.64-0.94) and had supplement therapy (AHR = 0.71, 95%CI: 0.57-0.87) were associated with lower mortality.

Conclusion: Survival among oral cancer patients in this tertiary hospital was poor. Older age and advanced disease at diagnosis were key drivers of mortality, highlighting the need for earlier detection, complete staging, and strengthened supportive care.

Keywords: Oral cancer, Survival analysis, Advanced stage, Distant metastases, Age, Sex differences, Thailand

References

[1] Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009;45(4—5):309—16. https://doi.org/10.1016/j.oraloncology.2008.06.002.

[2] Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 2020;6(1):92. https://doi.org/10.1038/s41572-020-00224-3.

[3] Villaret AB, Cappiello J, Piazza C, Pedruzzi B, Nicolai P. Quality of life in patients treated for cancer of the oral cavity requiring reconstruction: a prospective study. Acta Otorhinolaryngol Ital 2008;28(3):120—5.

[4] Ihara Y, Kato H, Tashimo Y, Iizumi Y, Fukunishi Y, Sato H, et al. Changes in oral function, swallowing function, and quality of life in patients with head and neck cancer: a prospective cohort study. BMC Oral Health 2022;22(1):293. https://doi.org/10.1186/s12903-022-02329-5.

[5] Ross S, Mosher CE, Ronis-Tobin V, Hermele S, Ostroff JS. Psychosocial adjustment of family caregivers of head and neck cancer survivors. Support Care Cancer 2010;18(2): 171—8. https://doi.org/10.1007/s00520-009-0641-3.

[6] Rogers SN, Tsai HH, Cherry MG, Patterson JM, Semple CJ. Experiences and needs of carers of patients with head and neck cancer: a systematic review. Psychooncology 2024; 33(10):e9308. https://doi.org/10.1002/pon.9308.

[7] Jokar M, Namavari N, Moshiri SA, Jahromi HK, Rahmanian V. The incidence of oral cavity cancer in Iran: A systematic review and meta-analysis. Cancer Rep (Hoboken) 2023;6(6):e1836. https://doi.org/10.1002/cnr2.1836.

[8] Tangjaturonrasme N, Vatanasapt P, Bychkov A. Epidemiology of head and neck cancer in Thailand. Asia Pac. J Clin Oncol 2018;14(1):16—22. https://doi.org/10.1111/ajco.12757.

[9] Rumgay H, Nethan ST, Shah R, Vignat J, Ayo-Yusuf O, Chaturvedi P, et al. Global burden of oral cancer in 2022 attributable to smokeless tobacco and areca nut consumption: a population attributable fraction analysis. Lancet Oncol 2024;25(11):1413—23. https://doi.org/10.1016/S1470-2045(24)00458-3.

[10] Zanoni DK, Montero PH, Migliacci JC, Shah JP, Wong RJ, Ganly I, et al. Survival outcomes after treatment of cancer of the oral cavity (1985-2015). Oral Oncol 2019;90:115—21. https://doi.org/10.1016/j.oraloncology.2019.02.001.

[11] Gangane NM, Ghongade PV, Patil BU, Atram M. Oral cavity cancer incidence and survival trends: A population-based study. J Cancer Res Therapeut 2024;20(5):1446—52. https://doi.org/10.4103/jcrt.jcrt_2720_22.

[12] Warnakulasuriya S, Filho AM. Oral cancer in the South and South-East Asia Region, 2022: incidence and mortality. Oral Dis 2025;31(5):1398—405. https://doi.org/10.1111/odi.15369.

[13] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3): 229—63. https://doi.org/10.3322/caac.21834.

[14] Vatanasapt P, Suwanrungruang K, Kamsa-Ard S, Promthet S, Parkin MD. Epidemiology of oral and 12 JOURNAL OF HEALTH RESEARCH 2026;XX:1—13 ORIGINAL STUDY pharyngeal cancers in Khon Kaen, Thailand: a high incidence in females. Asian Pac J Cancer Prev APJCP 2011; 12(10):2505—8.

[15] Filho AM, Warnakulasuriya S. Epidemiology of oral cancer in South and South-East Asia: Incidence and mortality. Oral Dis 2024;30(8):4847—54. https://doi.org/10.1111/odi.14906.

[16] Chen J, Selokar A, Ho FDV, Jacomina LE, Feliciano EJG, Uy J, et al. Head and Neck Cancer in Southeast Asia: 2022 Incidence, Mortality, and Projections to 2050. Laryngoscope 2025;135(12):4742—53. https://doi.org/10.1002/lary.32450.

[17] Argirion I, Zarins KR, Defever K, Suwanrungruang K, Chang JT, Pongnikorn D, et al. Temporal changes in head and neck cancer incidence in Thailand suggest changing oropharyngeal epidemiology in the region. J Global Oncol 2019;5:1—11. https://doi.org/10.1200/JGO.18.00219.

[18] Loyha K, Vatanasapt P, Promthet S, Parkin DM. Risk factors for oral cancer in northeast Thailand. Asian Pac J Cancer Prev APJCP 2012;13(10):5087—90. https://doi.org/10.7314/apjcp.2012.13.10.5087.

[19] Kruaysawat W, Aekplakorn W, Chapman RS. Survival time and prognostic factors of oral cancer in Ubon Ratchathani Cancer Center. J Med Assoc Thail 2010;93(3):278—84.

[20] Juntanong N, Siewchaisakul P, Bradshaw P, Vatanasapt P, Chen SL, Yen AM, et al. Prevalence and factors associated with oral pre-malignant lesions in Northeast Thailand. Asian Pac J Cancer Prev APJCP 2016;17(8):4175—9.

[21] Chaimay B, Woradet S, Putthanachote N. Survival and factors associated with mortality among esophageal cancer patients at a tertiary hospital in Northeastern Thailand. J Health Res 2026;40(1):10—8. https://doi.org/10.56808/2586-940X.1179.

[22] Sungwalee W, Vatanasapt P, Suwanrungruang K, Promthet S. Comparing survival of oral cancer patients before and after launching of the universal coverage scheme in Thailand. Asian Pac J Cancer Prev APJCP 2016;17(7): 3541—4.

[23] Gatta G, Botta L, Sanchez MJ, Anderson LA, Pierannunzio D, Licitra L, et al. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. Eur J Cancer 2015; 51(15):2130—43. https://doi.org/10.1016/j.ejca.2015.07.043.

[24] Schwam ZG, Judson BL. Improved prognosis for patients with oral cavity squamous cell carcinoma: Analysis of the National Cancer Database 1998-2006. Oral Oncol 2016;52: 45—51. https://doi.org/10.1016/j.oraloncology.2015.10.012.

[25] Geleijnse G, Chiang RC, Sieswerda M, Schuurman M, Lee KC, van Soest J, et al. Prognostic factors analysis for oral cavity cancer survival in the Netherlands and Taiwan using a privacy-preserving federated infrastructure. Sci Rep 2020; 10(1):20526. https://doi.org/10.1038/s41598-020-77476-2.

[26] Oliveira LL, Bergmann A, Melo AC, Thuler LC. Prognostic factors associated with overall survival in patients with oral cavity squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2020;25(4):e523—31. https://doi.org/10.4317/medoral.23558.

[27] Pruegsanusak K, Peeravut S, Leelamanit V, Sinkijcharoenchai W, Jongsatitpaiboon J, Phungrassami T, et al. Survival and prognostic factors of different sites of head and neck cancer: an analysis from Thailand. Asian Pac J Cancer Prev APJCP 2012;13(3):885—90. https://doi.org/10.7314/apjcp.2012.13.3.885.

[28] Zanoni DK, Valero C, McGill MR, Montero PH, Shah JP, Wong RJ, et al. Distant metastasis in oral squamous cell carcinoma: Does the neutrophil-to-lymphocyte ratio act as a surrogate of the host immune status? Oral Oncol 2022;124: 105641. https://doi.org/10.1016/j.oraloncology.2021.105641.

[29] Bell RB, Kademani D, Homer L, Dierks EJ, Potter BE. Tongue cancer: Is there a difference in survival compared with other subsites in the oral cavity? J Oral Maxillofac Surg 2007;65(2):229—36. https://doi.org/10.1016/j.joms.2005.11.094.

[30] Siewchaisakul P, Sarakarn P, Vatanasapt P, Chen SL, Yen AM. Sex differences in the heterogeneous dynamic incidence of oral cancer: a comparison between Taiwan and Thailand. Biomed Res Int 2020;2020:9321246. https://doi.org/10.1155/2020/9321246.

[31] Bakshi J, Kaur N, Tiwana H, Verma RK, Panda NK, Patro SK. Survival analysis of oral squamous cell carcinoma patients attending tertiary care centre of North India. Indian J Surg Oncol 2023;14(1):234—42. https://doi.org/10.1007/s13193-020-01187-3.

[32] Hong X, Quimby AE, Mavedatnia D, Pickett AT, Corsten M, Zhang T, et al. oral cavity squamous cell carcinoma in young patients: a multi-institutional study of the Canadian Head & Neck Collaborative Research Initiative. J Otolaryngol Head Neck Surg 2025;54:19160216251351562. https://doi.org/10.1177/19160216251351562.

[33] Wang CH, Wang HM, Pang YP, Yeh KY. Early nutritional support in non-metastatic stage IV oral cavity cancer patients undergoing adjuvant concurrent chemoradiotherapy: analysis of treatment tolerance and outcome in an area endemic for betel quid chewing. Support Care Cancer 2012; 20(6):1169—74. https://doi.org/10.1007/s00520-011-1192-y.

[34] Kim JM, Sung MK. The efficacy of oral nutritional intervention in malnourished cancer patients: a systemic review. Clin Nutr Res 2016;5(4):219—36. https://doi.org/10.7762/cnr.2016.5.4.219.

[35] Ellis MA, Graboyes EM, Wahlquist AE, Neskey DM, Kaczmar JM, Schopper HK, et al. Primary surgery vs radiotherapy for early stage oral cavity cancer. Otolaryngol Head Neck Surg 2018;158(4):649—59. https://doi.org/10.1177/0194599817746909.

[36] Spiotto MT, Jefferson G, Wenig B, Markiewicz M, Weichselbaum RR, Koshy M. Differences in survival with surgery and postoperative radiotherapy compared with definitive chemoradiotherapy for oral cavity cancer: a national cancer database analysis. JAMA Otolaryngol Head Neck Surg 2017;143(7):691—9. https://doi.org/10.1001/jamaoto.2017.0012.

[37] Lin CY, Chen WC, Wen YW, Fan KH, Lin JC, Ng SH, et al. Comparing the clinical outcomes of initial surgery and primary definitive radiotherapy with a dosage of 6600 cGy or higher in cT1-2N0M0 oral cavity squamous cell carcinoma: A nationwide cohort study. Cancer Med 2024;13(10): e7127. https://doi.org/10.1002/cam4.7127.

Download

Share

COinS